← 프로그램 목록
ADCPhase 2Recruiting

Anti-CD19 Antibody-Drug Conjugate (Loncastuximab Tesirine)

ADC Therapeutics

비교

Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate)(ADC Therapeutics)은 CD19 표적 ADC로, Diffuse Large B-Cell Lymphoma; High-grade B-cell Lymphoma (HGBCL) 영역에서 개발·상용화 중입니다. 작용기전: targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 94.1% (ClinicalTrials.gov NCT05144009). PK: t½ 7 h. 차별점: unique toxicities related to the antigen target, linker, or payload that have limited their development.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 9일 (5일 전)PK/독성 2026년 7월 9일 (5일 전)

CD19

Diffuse Large B-Cell Lymphoma; High-grade B-cell Lymphoma (HGBCL)

Recruiting

Technology

구조모아 · PBD dimer payload

ADCs) represent an important therapeutic modality for the treat

that

linker, or payload that have limited their development

humanized anti-CD19 monoclonal antibody (RC58) was developed in the present study

unique toxicities related to the antigen target, linker, or payload that have limited their development

Mechanism of Action

targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen

T-cell engager that binds to both CD19 on B cells and CD3 on T cells, facilitating antibody-dependent cytotoxicity

payload that have limited their development

CD19-positive

resistance to multiple therapies

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 48건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: Phase 3 · Phase 2 · Phase 2, Phase 3 · Phase 1…
  • Status: No longer available · Completed · Active, not recruiting
  • 주요 endpoint: Sepsis-related toxicity of antibody-drug conjugate. · Causality assessment of reported cardiovascular events according to the WHO system · Description of the type of sepsis-related toxicities depending on the category of ADC · Description of the drug-drug interactions associated with sepsis-related adverse events · Description of the population of patients having a sepsis-related adverse events
  • 등록된 결과: ORR 94.1%
  • 핵심: The main objective of the trial is to assess the efficacy and tolerability of Lonca-R in unfit and frail participants wi…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate)은 어떤 치료제인가요?
Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate)(ADC Therapeutics)은 CD19 표적 ADC로, Diffuse Large B-Cell Lymphoma; High-grade B-cell Lymphoma (HGBCL) 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate)의 임상 단계는?
Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate)의 현재 단계는 Phase 2입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.